Slide 1: Annual General Meeting 20 November 2017
Biotrom Annual General Meeting 20% November 2017
Slide 2: Forward Looking Statements
Forward Looking Statements This presenta'on may contain forward looking statements with respect to the financial condi'on, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objec'ves of its management. These statements are statements that
Slide 3: Investment Highlights
Investment Highlights • Biotron is designing, developing and commercialising a plaUorm of an'viral drugs with a novel mode of ac'on – able to target a wide variety of viral infec'ons • Pipeline of programs in high value, high need markets • Progress in clinical lead program (BIT225) provides strong
Slide 4: Biotron Limited – Snap Shot
Biotron Limited – Snap Shot BROAD PLATFORM WITH NEW CLASS OF ANTIVIRAL DRUGS HIV-1 ERADICATION HEPATITIS C VIRUS (HCV) HBV & EARLY STAGE PROGRAMS - Targe'ng HIV-1 in long-lived - New class of HCV drug - Pipeline of early stage reservoirs - Phase 2 completed programs, including: - Phase 2 trial in pr
Slide 5: Key Achievements FY 2017
Key Achievements FY 2017 • Commenced Phase 2 clinical trial of BIT225 and Combina'on An'retroviral Therapy (cART) in Feb’17 • Fully recruited in July ‘17; Dosing with BIT225/placebo completed; data pending • Demonstrated significant and accelerated reduc'on in HIV-1 viral load following addi'on of BI
Slide 6: Commercialisation – Key Focus
CommercialisaUon – Key Focus • Three tac'cal priori'es: • Partnering lead clinical program - BIT225 for HIV-1 eradica'on • Partnering one or more preclinical programs – e.g. HBV • Execute a regional licensing deal in China - HCV program remains a great opportunity
Slide 7: HIV-1 Eradication
HIV-1 EradicaUon Current drugs do not eradicate HIV-1 virus • HIV-1 remains hidden in reservoirs, leading to chronic, life-long infec'on • Invisible to body’s immune defenses • Not sensi've to an'-HIV-1 drugs • New mode of ac'ons drugs are needed to eradicate or cure HIV-1 infec'on Why is HIV-1 erad
Slide 8: HIV-1 Eradication: BIT225-009 Trial
HIV-1 EradicaUon: BIT225-009 Trial BIT225 or placebo added to ART • 36 HIV-1+ve, treatment-naïve subjects commencing ART • Randomised 2:1 (drug:placebo) • BIT225 or placebo added to ART for first 12 weeks of treatment • Read-out • Impact on virus levels; reduc'on of immune ac'va'on markers • Fully re
Slide 9: HIV-1 Eradication: BIT225-009 Trial
HIV-1 EradicaUon: BIT225-009 Trial • Fully recruited July; last pa'ent, last dose in mid-October • Three month follow-up period post-dosing with BIT225/placebo • Addi'onal samples collected from pa'ents throughout this next 3 month period • Post-trial laboratory analyses on samples from treatment pe
Slide 10: Commercialisation: BIT225 HIV-1 Eradication
CommercialisaUon: BIT225 HIV-1 EradicaUon • Several pharmaceu'cal companies have ac've HIV-1 “Cure” Programs • Iden'fied and qualified poten'al partners • Posi've outcomes – BIT225 clinical trial - key to progressing commercialisa'on discussions • Poten'al partners have defined their success criteria –
Slide 11: Commercialisation: Preclinical Programs – HBV
CommercialisaUon: Preclinical Programs – HBV • Hepa''s B virus (HBV) therapeu'c space has significant interest from pharma & biotech companies • Biotron’s HBV program is elici'ng early interest from poten'al partners • In vitro data on several candidate compounds includes evidence of reduc'on of indu
Slide 12: Commercialisation: Regional Licensing – China, HCV Program
CommercialisaUon: Regional Licensing – China, HCV Program • The new HCV drugs (e.g. Solvadi) may cause reac'va'on of HBV in HCV/HBV coinfected pa'ents • Resulted in US FDA “Black Box” Warning on new HCV drugs • 30 million HCV-infected people in China, compared to 3-5 million in USA • 93 million chro
Slide 13: Commercialisation: Regional Licensing – China, HCV Program
CommercialisaUon: Regional Licensing – China, HCV Program • Seeking partnerships for commercialisa'on of BIT225 for the treatment of HCV in China • Appointed a Shanghai-based corporate advisor with extensive experience in cross-border transac'ons in the healthcare space • Developed a well qualified p
Slide 14: Unlocking Value for Other Virus Targets
Unlocking Value for Other Virus Targets Library of compounds designed to target viroporins found in some viruses: Ini'ally >250 compounds designed and synthesised; library now ~350 OTHER “HITS” IN LIBRARY include: • Influenza A and B • Hepa''s B virus (HBV) • Coronaviruses (Including SARS) • Epstein-
Slide 15: Unlocking Value for Other Virus Targets
Unlocking Value for Other Virus Targets Biotron’s Viroporin approach enables the targe'ng of a wide range of viral diseases; examples include: • Respiratory Viruses such as Respiratory Syncy'al Virus (RSV), Influenza, & Coronaviruses (leading cause of “common cold”) • Flaviviruses such as Zika Virus
Slide 16: Summary
Summary • HIV EradicaUon • Engaged with the right poten'al partners • Wai'ng for data from trial but con'nue to engage with pharma • Preclinical Programs • HBV has promise as a preclinical candidate for joint development. HBV therapeu'c space is very hot. • BIT225 results validate the plaUorm; poten